Trial Profile
A Phase 2, Randomized, Double-Blind Study of Ipilimumab Administered at 3 mg/kg vs 10 mg/kg in Adult Subjects With Metastatic Chemotherapy-Naive Castration Resistant Prostate Cancer Who Are Asymptomatic or Minimally Symptomatic
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 14 Aug 2019 Status changed to completed.
- 05 Apr 2019 This trial has been completed in Germany and Spain as per European Clinical Trials Database record
- 03 May 2017 This trial has been completed in Netherlands as per European Clinical Trials Database record.